• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
IRWD

IRWD

Ironwood Pharmaceuticals, Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS

USD3.24

-0.04 (-1.22%)

Rating:B

Company Profile

CEO

Thomas A. McCourt

IPO Date

2010-02-03

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

US

Market Metrics

Open

$3.30

Prev. Close

$3.28

Day Low

$3.19

Day High

$3.30

52W Low

$0.56

52W High

$5.78

Market Cap

$0.53B

Volume

2.60M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

39.7%

Avg Negative

7.4%

Avg Neutral

52.6%

News Feed

Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

Business Wire·6/16/2021·↑ positive

Moving Average Crossover Alert: Ironwood Pharmaceuticals (IRWD)

Zacks Investment Research·5/10/2021·↑ positive

Ironwood Pharmaceuticals, Inc. (IRWD) CEO Thomas McCourt on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/9/2021·↓ negative

Ironwood's (IRWD) Q1 Earnings Beat, 2021 Guidance Muted

Zacks Investment Research·5/7/2021·↑ positive

Recap: Ironwood Pharmaceuticals Q1 Earnings

Benzinga·5/6/2021·↑ positive

Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program

Business Wire·5/6/2021·↑ positive

Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire·2/19/2021·↑ positive

Ironwood (IRWD) Q4 Earnings Beat on Solid Linzess Sales

Zacks Investment Research·2/18/2021·↑ positive

Ironwood Pharmaceuticals, Inc.'s (IRWD) CEO Mark Mallon on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha·2/17/2021·↓ negative

Ironwood Pharmaceuticals (IRWD) Surpasses Q4 Earnings and Revenue Estimates

Zacks Investment Research·2/17/2021·↑ positive